Hearing loss is the largest single modifiable risk factor for dementia in the Lancet Commission's 2024 framework, accounting for about 7 percent of global cases. That number raised eyebrows when it first appeared in the 2017 Lancet report, was upheld in the 2020 update, and survived the 2024 revision. The signal is robust across observational cohorts, biologically plausible, and now backed by the first randomized trial showing that treating hearing loss can slow cognitive decline in higher-risk adults. The honest version, which the Commission is careful to use, is "linked to," not "causes." That qualifier is doing real work.
This post walks through what the evidence actually shows, why hearing loss might affect cognition, what the ACHIEVE trial added in 2023, and what a practical response looks like.
The short answer: Untreated midlife hearing loss is associated with substantially higher dementia risk. A 2023 randomized trial showed that hearing aids slowed three-year cognitive decline by about 48 percent in higher-risk adults. Get a baseline hearing test by 50, treat any loss promptly, and revisit if anything changes.
What does the observational evidence show?
The foundational paper is Lin et al., 2011, in Archives of Neurology. The team followed 639 adults aged 36 to 90 from the Baltimore Longitudinal Study of Aging for a median of nearly 12 years. After adjusting for age, sex, race, education, and cardiovascular risk, the risk of incident dementia rose with hearing loss severity. Mild loss was associated with about double the dementia risk. Moderate loss tripled it. Severe loss raised it by a factor of about five. The relationship was dose-dependent and held up after extensive adjustment.
That single study would not be enough. The Loughrey et al., 2018, meta-analysis in JAMA Otolaryngology pooled 36 cohort studies covering tens of thousands of older adults. It confirmed the association across populations: age-related hearing loss was significantly linked to cognitive impairment (odds ratio 2.0), dementia (HR 1.28 per 10 dB of loss), and Alzheimer's disease specifically. The 2024 Lancet Commission used this body of work to land on its 7 percent population-attributable fraction, the share of dementia cases attributable to midlife hearing loss in a counterfactual world where everyone with treatable loss got treated.
Why might hearing loss affect cognition?
The mechanism question matters because association is not causation, and the policy question (treat or not?) depends on whether the relationship is causal. The Lancet Commission lays out three plausible pathways.
Cognitive load. When sound input is degraded, the brain compensates by recruiting prefrontal regions to parse what is being said. That borrowed capacity is not available for encoding the content. People with untreated hearing loss often describe being exhausted after social events; the exhaustion is real and metabolic.
Auditory cortex atrophy. Chronic under-use of an input pathway is followed, over years, by structural changes downstream. Imaging studies have found accelerated volume loss in auditory cortex and hippocampus among adults with untreated hearing loss.
Social withdrawal. Hearing loss makes conversation effortful and embarrassing. Adults with untreated loss withdraw from group settings, reduce social contact, and experience more loneliness. Social isolation is itself an independent dementia risk factor in the Lancet model. So one part of the hearing-loss effect probably runs through the cognitive reserve literature: less effortful, novel, socially-embedded engagement, less reserve.
These mechanisms are not mutually exclusive. The most likely picture is that all three contribute, in proportions that vary by person.
What did the ACHIEVE trial add?
The 2023 ACHIEVE trial, published in The Lancet, was the first major randomized test of the question. Lin and colleagues recruited 977 adults aged 70 to 84 with untreated mild-to-moderate hearing loss and randomized them to a comprehensive hearing intervention (audiologist fitting, hearing aids, counseling) or a health-education control. The primary outcome was three-year change on a global cognitive composite.
The headline result was null. Across the full sample, hearing aids did not slow cognitive decline more than health education. That null result deserves to be read carefully, not waved away.
The pre-specified subgroup analysis was where the action was. The trial was designed across two parallel cohorts: a higher-risk group recruited from the ARIC cardiovascular cohort, and a lower-risk group recruited from the community. In the higher-risk group, hearing aids produced a 48 percent reduction in three-year cognitive decline (a clinically meaningful difference on the composite outcome). In the lower-risk healthy group, the effect was essentially flat.
"The benefits of hearing intervention varied substantially across populations, with the largest cognitive benefit observed in adults with greater cognitive risk."
Lin et al., 2023, The Lancet
The interpretation the Lancet Commission landed on, and the one we think the data support, is that hearing aids matter most in adults whose brains are already under cardiovascular and metabolic stress. In healthier-than-average older adults, the marginal benefit over three years is hard to detect. That is a more nuanced finding than saying hearing aids stop dementia, and it is closer to the truth.
What does this mean in practice?
A few specific actions follow from the literature, ordered by leverage:
- Get a baseline hearing test by age 50. Hearing loss accumulates slowly, and most people miss the early phase. The ASHA recommendation is a baseline at 50 and a re-test every three years if normal.
- Treat midlife loss promptly when you find it. The Lancet Commission's population-attributable estimate is built on midlife exposure. The window where treatment plausibly matters most is 45 to 65, before social and cognitive habits have rearranged around the deficit.
- Use the OTC market for mild-to-moderate loss. The FDA's 2022 ruling on over-the-counter hearing aids made decent devices available at one-tenth of clinical-fit prices. For severe loss, single-sided deafness, or sudden onset, see an audiologist.
- Protect what you have. Noise exposure, ototoxic medications, and untreated cardiovascular risk all accelerate hearing loss. Earplugs at concerts cost almost nothing.
- Read the rest of the picture. Hearing loss is one of fourteen modifiable factors in the Lancet's 2024 dementia model. Treating it in isolation is good. Treating it alongside the others, sleep, exercise, diet, social engagement, is much better. See our brain health guide for the integrated picture.
The honest limits
Most of the dementia-risk evidence on hearing loss is observational, which means residual confounding by cardiovascular health, education, and socioeconomic factors is hard to fully rule out. The ACHIEVE trial's null primary outcome is a real result, not a footnote. The 7 percent population-attributable fraction is a counterfactual estimate that assumes a world where every case of treatable hearing loss was treated; it is not a per-person prediction.
What the evidence does support is straightforward: untreated hearing loss is bad for cognition, hearing aids appear to slow decline in higher-risk adults, and the cost of acting on this information is low. The cost of ignoring it, on the population scale the Commission is reasoning at, is substantial.